Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Advanced Unresectable Hepatocellular Carcinoma
NCT00071994Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2004
- Primary completion
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoint: Progression-free survival rate at 4.5 months. Started Feb 2004; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00071994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071994.